The Technical Analyst
Foghorn Therapeutics Inc. [FHTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Foghorn Therapeutics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.18% $5.16
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 219.64 mill |
| EPS: | -2.34 |
| P/E: | -2.21 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 42.57 mill |
| Avg Daily Volume: | 0.163 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.21 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.38x |
| Company: PE -2.21 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.53 - 5.80 ( +/- 12.31%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-16 | Humer Kristian | Buy | 275 000 | Stock Option (Right to buy) |
| 2024-04-16 | Humer Kristian | Buy | 0 | |
| 2024-03-11 | Cavalie Fanny | Sell | 11 000 | Common Stock |
| 2024-01-24 | Gottschalk Adrian | Buy | 300 000 | Stock Option (right to buy) |
| 2024-01-24 | Cardama Alfonso Quintas | Buy | 60 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 42.86 |
| Last 90 transactions |
| Buy: 4 432 955 | Sell: 2 595 211 |
Forecast:
16:00 - $5.14
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.14
Forecast 2: 16:00 - $5.14
Forecast 3: 16:00 - $5.14
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.16 (2.18% ) |
| Volume | 0.0457 mill |
| Avg. Vol. | 0.163 mill |
| % of Avg. Vol | 28.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FHTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-16 07:00:00 - Press Release
Foghorn Therapeutics Strengthens Financial Leadership With Appointment Of Kristian Humer As Chief Financial Officer
Cambridge, mass., april 16, 2024 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that kristian humer will join the company as chief financial officer (cfo) on april 16, 2024. mr. humer joins foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more than 20 years of experience in the financial industry.
2024-04-09 16:30:00 - Press Release
Foghorn Therapeutics Presents New Preclinical Data On Potential First-in-class Brm Selective Inhibitor Fhd-909 And Selective Cbp And Selective Ep300 Degrader Oncology Programs
First-in class brm (smarca2) selective inhibitor fhd-909 demonstrated favorable tolerability and dose-dependent single agent activity in brg1 mutated cancers preclinically; ind filing on track for q2 2024
2024-04-05 07:00:00 - Press Release
Foghorn Therapeutics To Participate In Needham's 23rd Annual Virtual Healthcare Conference
Company presentation and fireside chat on april 11th at 11:45 a.m. et company presentation and fireside chat on april 11th at 11:45 a.m. et
2024-03-26 07:00:00 - Press Release
Foghorn To Host Conference Call And Webcast On Pipeline Of Potential First-in-class Medicines In Conjunction With The 2024 Aacr Annual Meeting
Company management will review key pipeline programs, including an update on fhd-286 for aml, new preclinical data for the brm selective inhibitor fhd-909 and for its selective cbp and ep300 degrader programs
2024-03-07 07:00:00 - Press Release
Foghorn Therapeutics Provides Financial Update For 2023 And 2024 Strategic Outlook
• dose escalation in fhd-286 combination study in aml continues to progress; clinical data anticipated in the second half of 2024
Latest News
2024-04-02 10:56:04 - Zacks Investment Research
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 105.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2024-03-26 07:00:00 - GlobeNewsWire
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs
2024-03-13 13:00:23 - Zacks Investment Research
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-13 10:56:21 - Zacks Investment Research
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
The consensus price target hints at a 124.3% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-07 09:21:05 - Zacks Investment Research
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.69 per share a year ago.
2024-03-05 16:48:00 - GlobeNewsWire
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024
2024-02-12 03:46:03 - Zacks Investment Research
Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2024-02-09 11:05:15 - Zacks Investment Research
Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
Foghorn (FHTX) gains 55% as its strategic collaboration partner, Lilly, selects the pre-clinical candidate, FHD-909, for clinical development.
2023-12-26 13:31:07 - Zacks Investment Research
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's Why
Foghorn Therapeutics Inc. (FHTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-10-04 08:00:00 - GlobeNewsWire
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for its BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference. The conference will be held October 11–15, 2023, in Boston, Massachusetts.